The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), Johnson & Johnson (Gold) and Lilly (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ERIC 2024 | Engineering stromal cells to express T-cell factors to induce CLL cell proliferation
Marek Mráz, PhD, Central European Institute of Technology, Brno, Czech Republic, discusses the development of a model for chronic lymphocytic leukemia (CLL) cells by engineering three T-cell factors (CD40, IL-4, and IL-21) into HS5 stromal cells. This model revealed that the combination of these factors induces robust CLL cell proliferation, offering insights into potential drug interventions that effectively block proliferation. This interview took place at the 2024 European Research Initiative on CLL (ERIC) Meeting in Barcelona, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
